SUBSCRIBE
SUBSCRIBE
News   Drug Development

AstraZeneca PLC, Johnson & Johnson Drugs for Schizophrenia May Exacerbate Loss of Brain Tissue, Study Finds

February 8, 2011 | 
1 min read
Bloomberg -- Anti-psychotic drugs from AstraZeneca Plc and Johnson & Johnson may lead to loss of brain tissue or exacerbate declines in brain volume caused by schizophrenia, a study in the Archives of General Psychiatry found.
Clinical research Postmarket research
AstraZeneca Pharmaceuticals LP Johnson & Johnson Family of Companies
MORE ON THIS TOPIC
Podcast
Deals Roll at JPM26, Policy Front and Center, IPOs Are Back, FDA Stays Busy
January 14, 2026
 · 
2 min read
 · 
Heather McKenzie
Manhattan, New York USA - July 9, 2011: Pfizer letter sign on the building's Headquarters. Pfizer's is the largest pharmaceutical company in the world.
Business
JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff
January 13, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Stairs Leading to Flying Paper Plane - Success, Growth, and Freedom, 3D Render
ADCs
Lung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADC
January 13, 2026
 · 
3 min read
 · 
Tristan Manalac
Cartoon tiny people work with scientific equipment, develop innovations, new projects ideas. Startup business teamwork, solution development through science knowledge dark concept vector illustration
Collaboration
JPM26: BMS’s Early-Stage Bets Are Happening Now, Amid Pharma’s Late-Stage Frenzy
January 12, 2026
 · 
3 min read
 · 
Annalee Armstrong